Danbot: Strip excess bold

2026-03-22T09:28:44Z

Strip excess bold

Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template

2026-03-19T14:39:44Z

Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template

Show changes

Ostermayer: Created page with "Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: '''acute beryllium disease''' (ABD), a chemical pneumonitis from high-dose inhalation, and '''chronic beryllium disease''' (CBD, berylliosis), a cell-mediated granulomatous lung disease that is '''clinically, radiographically, and histopathologically indistinguishable from sarcoidosis'''.Balmes JR, et al. An official American..."

2026-03-11T15:25:57Z

Created page with "Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: '''acute beryllium disease''' (ABD), a chemical pneumonitis from high-dose inhalation, and '''chronic beryllium disease''' (CBD, berylliosis), a cell-mediated granulomatous lung disease that is '''clinically, radiographically, and histopathologically indistinguishable from sarcoidosis'''.<ref name="ATS2014">Balmes JR, et al. An official American..."

New page

Beryllium toxicity encompasses two distinct pulmonary diseases caused by exposure to beryllium metal, alloys, or compounds: '''acute beryllium disease''' (ABD), a chemical pneumonitis from high-dose inhalation, and '''chronic beryllium disease''' (CBD, berylliosis), a cell-mediated granulomatous lung disease that is '''clinically, radiographically, and histopathologically indistinguishable from [[sarcoidosis]]'''.<ref name="ATS2014">Balmes JR, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. ''Am J Respir Crit Care Med''. 2014;190(10):e34-e59.</ref> ABD is now rare due to workplace exposure limits. CBD remains an active occupational health concern. Beryllium is classified as a '''Group 1 carcinogen''' (lung cancer) by IARC.<ref name="OSHA">Beryllium — Health Effects. Occupational Safety and Health Administration (OSHA).</ref> The ED physician's key role is to consider beryllium exposure in any patient diagnosed with "sarcoidosis" who has occupational exposure, and to manage acute inhalational injury.

==Background==
*Beryllium is a lightweight metal used in aerospace, defense, nuclear weapons, electronics, telecommunications, dental alloys, high-technology ceramics, metal recycling, and automotive manufacturing<ref name="StatPearls">Berylliosis. ''StatPearls''. NCBI Bookshelf. Updated February 2023.</ref>
*Estimated 134,000 workers in the United States are exposed to beryllium<ref name="Wikipedia">Berylliosis. ''Wikipedia''. Updated January 2026.</ref>
*'''Two distinct diseases:'''
**'''Acute beryllium disease (ABD):''' Direct chemical/toxic pneumonitis from high-dose inhalation; dose-dependent; now rare due to exposure controls; onset within hours to days of heavy exposure; most patients recover with removal from exposure<ref name="NCBI">Epidemiologic and Clinical Studies of Beryllium Sensitization and Chronic Beryllium Disease. In: ''Managing Health Effects of Beryllium Exposure''. National Academies Press; 2008.</ref>
**'''Chronic beryllium disease (CBD):''' Cell-mediated (type IV) hypersensitivity reaction; requires prior sensitization; '''not dose-dependent''' — can occur even at levels below OSHA PEL; latency period '''3 months to 30+ years''' from initial exposure<ref name="StatPearls"/>
*'''Pathogenesis of CBD:'''
**Beryllium acts as a hapten → presented by MHC class II (especially '''HLA-DPB1 Glu69''') to CD4+ T cells → T-cell sensitization → upon re-exposure, proliferation of beryllium-specific CD4+ T cells → release of TNF-α, IL-2, IFN-γ → '''noncaseating granuloma formation'''<ref name="ATS2014"/>
**Essentially identical pathogenesis to sarcoidosis (granulomatous inflammation driven by CD4+ T-cell response to an antigen)
*'''Beryllium sensitization (BeS):''' Immune sensitization without clinical disease; detected by beryllium lymphocyte proliferation test (BeLPT); 2–6% of exposed workers become sensitized; among sensitized workers, ~66% progress to CBD<ref name="StatPearls"/>
*Skin exposure (not just inhalation) may cause sensitization<ref name="OSHA"/>
*'''Chelation therapy is ineffective''' — beryllium is poorly soluble and persists in the body for the individual's lifetime<ref name="ATS2014"/>
*OSHA permissible exposure limit: 0.2 µg/m³ (8-hour TWA); cases still occur below this threshold<ref name="OSHA"/>

==Clinical Features==
'''Acute beryllium disease (rare):'''
*Onset hours to days after heavy inhalation exposure
*Severe cough, dyspnea, chest tightness
*Chemical pneumonitis → pulmonary edema → [[ARDS]] in severe cases<ref name="NCBI"/>
*Rhinitis, pharyngitis, tracheobronchitis with upper airway irritation
*May be fulminant and fatal if exposure is massive
*Most patients recover over weeks to months if removed from exposure, though may recur with re-exposure<ref name="NCBI"/>

'''Chronic beryllium disease:'''
*'''Insidious onset''' — latency period of months to '''decades''' (mean ~10 years) after initial exposure<ref name="StatPearls"/>
*Progressive '''dyspnea on exertion''' (most common symptom)
*Persistent dry cough
*Fatigue, weight loss
*Fever, night sweats (mimics [[tuberculosis]] or lymphoma)
*Chest pain (uncommon)
*'''Physical exam:'''
**May be '''normal''' early in disease (many cases detected by surveillance BeLPT before symptoms develop)
**Bibasal inspiratory crackles
**Lymphadenopathy
**Hepatosplenomegaly (rare)
*'''Extrapulmonary manifestations''' (less common than sarcoidosis):
**'''Skin:''' Granulomatous skin lesions — most common extrapulmonary manifestation; contact dermatitis; subcutaneous nodules at sites of skin implantation (embedded beryllium particles)<ref name="CBD">Rossman MD. Chronic beryllium disease: diagnosis and management. ''Environ Health Perspect''. 1996;104(Suppl 5):945-947.</ref>
**Granulomatous hepatitis
**[[Hypercalcemia]]
**Nephrolithiasis (kidney stones)
**Uveitis (less common than in sarcoidosis)

'''Beryllium dermatitis:'''
*Contact dermatitis from skin exposure to beryllium salts
*Patients who develop beryllium contact dermatitis are at '''high risk''' for beryllium sensitization and subsequent CBD<ref name="ClevelandClinic">Berylliosis (Chronic Beryllium Disease). Cleveland Clinic. Updated November 2025.</ref>

==Differential Diagnosis==
*'''[[Sarcoidosis]]''' — the '''most important differential'''; clinically indistinguishable from CBD; any patient diagnosed with "sarcoidosis" who has a history of beryllium exposure should be evaluated for CBD with BeLPT<ref name="Merck">Beryllium Disease. ''Merck Manual Professional Edition''. Updated October 2023.</ref>
*[[Tuberculosis]] (caseating granulomas; AFB stain/culture positive; unlike CBD which has noncaseating granulomas)
*[[Hypersensitivity pneumonitis]] (exposure history differs; bronchiolocentric poorly formed granulomas vs. well-formed granulomas of CBD)
*Other pneumoconioses ([[silicosis]], [[asbestosis]])
*[[Idiopathic pulmonary fibrosis]]
*Fungal infections ([[histoplasmosis]], [[coccidioidomycosis]] — also cause granulomas)
*Lymphoma (hilar lymphadenopathy, constitutional symptoms)
*[[Lung cancer]] (beryllium is a Group 1 carcinogen; may coexist with CBD)
*'''For acute beryllium disease:'''
**[[Toxic inhalation]] injury (chlorine, phosgene, metal fume fever)
**Acute [[eosinophilic pneumonia]]
**[[Pneumonia]]
**[[ARDS]] from other causes

==Evaluation==
===Workup===
'''History — the most critical diagnostic tool:'''
*'''Detailed occupational history:''' Current and all prior employment; specifically ask about aerospace, defense, nuclear, electronics, telecommunications, dental laboratory, ceramics, metal alloy machining, metal recycling, and jewelry work
*'''Do not rely on the patient knowing they were exposed''' — many workers are unaware that beryllium is present in their workplace (copper-beryllium alloys, aluminum-beryllium alloys are common); even clerical workers in beryllium facilities have developed sensitization<ref name="Wikipedia"/>
*Duration and intensity of exposure (though CBD can occur at very low levels)
*Household/bystander exposure (contaminated work clothing brought home)
*Latency period may be very long — ask about exposures decades ago

'''Laboratory (ED):'''
*CBC, CMP (renal function, calcium)
*'''Serum calcium:''' Hypercalcemia may occur (granulomatous production of 1,25-dihydroxyvitamin D, as in sarcoidosis)
*ACE level: Often elevated (same mechanism as sarcoidosis; nonspecific)
*ABG/VBG: Hypoxemia, especially with exercise
*ESR/CRP: May be elevated
*'''Beryllium lymphocyte proliferation test (BeLPT):''' NOT an ED test — requires specialized laboratory; performed on peripheral blood or BAL fluid; detects beryllium-specific T-cell sensitization; forms the basis of diagnosis<ref name="ATS2014"/>
**'''Two abnormal blood BeLPTs''' or '''one abnormal BAL BeLPT''' confirms beryllium sensitization
**Sensitivity ~75–90% for blood BeLPT; BAL BeLPT is more sensitive
*'''Note:''' There are no useful serum or urine beryllium levels for clinical diagnosis — body burden is not reflected by blood/urine concentrations, and beryllium is poorly soluble<ref name="ATS2014"/>

'''Imaging:'''

''Chest X-ray:''
*May be '''normal''' early in CBD<ref name="Merck"/>
*Abnormalities often '''indistinguishable from sarcoidosis:'''
**Bilateral hilar and mediastinal lymphadenopathy
**Diffuse reticulonodular infiltrates
**Upper-lobe predominance of parenchymal opacities
*Acute beryllium disease: diffuse bilateral hazy/ground-glass opacities → frank pulmonary edema pattern<ref name="NCBI"/>

''HRCT (more sensitive than CXR):''
*Ground-glass opacities
*Small parenchymal nodules (along bronchovascular bundles and subpleural — identical to sarcoidosis)
*Mediastinal and hilar lymphadenopathy
*Fibrosis, honeycombing in advanced disease
*May be normal in early CBD<ref name="Merck"/>

'''Pulmonary function tests''' (outpatient):
*'''Restrictive''' pattern most common (reduced FVC, reduced TLC)
*Reduced DLCO (often the earliest PFT abnormality)<ref name="StatPearls"/>
*May show obstructive or mixed pattern
*Exercise-induced desaturation (useful for detecting early disease)

===Diagnosis===
*'''Definitive diagnosis of CBD''' requires:<ref name="ATS2014"/>
**(1) History of beryllium exposure
**(2) Positive BeLPT (beryllium sensitization confirmed)
**(3) Granulomatous inflammation on lung biopsy
*'''Probable CBD''' can be diagnosed with two of these three criteria when the third is unavailable
*'''In the ED:''' Definitive diagnosis is not possible — the key is to '''consider the diagnosis''' in any patient presenting with a sarcoidosis-like picture who has occupational beryllium exposure history
*Any patient diagnosed with [[sarcoidosis]] who has '''any history of beryllium exposure''' should be referred for BeLPT testing to rule out CBD<ref name="Merck"/>
*Lung biopsy (transbronchial or surgical) shows '''noncaseating granulomas''' identical to sarcoidosis; special stains and cultures are negative for mycobacteria and fungi<ref name="StatPearls"/>
*BAL typically shows lymphocytosis with increased CD4:CD8 ratio (similar to sarcoidosis)

==Management==
'''Acute beryllium disease (chemical pneumonitis):'''
*'''Remove from exposure''' immediately
*Supplemental O2; high-flow or non-invasive ventilation as needed
*Intubation and mechanical ventilation for [[ARDS]]
*Systemic corticosteroids (methylprednisolone IV or prednisone PO) for significant pulmonary inflammation
*Bronchodilators for bronchospasm
*Standard [[ARDS]] management if severe (low tidal volume ventilation, prone positioning)
*Supportive care: IV fluids, monitoring
*Skin decontamination if dermal exposure (copious water irrigation; embedded beryllium particles may require surgical excision to prevent chronic granulomatous skin lesions)
*'''Chelation therapy is NOT effective''' for beryllium — the metal is poorly soluble and persists in tissue indefinitely<ref name="ATS2014"/>

'''Chronic beryllium disease:'''
*'''Remove from further beryllium exposure''' — though evidence that removal alone improves outcomes is limited; disease frequently progresses even after exposure ceases<ref name="ATS2014"/>
*'''Corticosteroids''' — first-line pharmacotherapy:<ref name="ATS2014"/>
**Prednisone 20–40 mg daily or every other day for 3–6 months
**Taper guided by symptoms, PFTs, and gas exchange
**Long-term low-dose maintenance may be necessary
*'''Steroid-sparing agents''' for patients who fail or cannot tolerate corticosteroids:
**Methotrexate (7.5 mg/week with folic acid; monitor CBC and LFTs every 8–12 weeks)<ref name="StatPearls"/>
**Azathioprine
**Mycophenolate mofetil
**Infliximab (under investigation)<ref name="NORD">Berylliosis. National Organization for Rare Disorders (NORD). Updated January 2023.</ref>
*Supplemental O2 to maintain SpO2 ≥90%
*Pulmonary rehabilitation
*Lung transplantation for end-stage disease (limited experience; effectiveness uncertain)<ref name="ATS2014"/>
*'''Beryllium sensitization without CBD:''' No treatment required; remove from exposure; periodic monitoring with PFTs, CXR, and BeLPT for progression to CBD<ref name="NORD"/>
*'''Lifelong follow-up:''' Serial PFTs, ABGs, CXR; patients with CBD require ongoing monitoring even if asymptomatic<ref name="StatPearls"/>

'''Reporting and occupational considerations:'''
*CBD is a '''compensable occupational illness''' — document exposure history thoroughly
*Federal workers exposed at DOE facilities may be eligible for compensation under the Energy Employees Occupational Illness Compensation Program<ref name="ATS2014"/>
*Report to OSHA / state occupational health authorities as appropriate
*Beryllium is a '''known human carcinogen''' — patients with CBD should be counseled about increased lung cancer risk and offered appropriate cancer surveillance<ref name="OSHA"/>

==Disposition==
*'''Admit:'''
**Acute beryllium disease with significant hypoxemia, respiratory distress, or chemical pneumonitis
**Suspected ARDS from acute inhalation
**New presentation of CBD with respiratory failure or significant hypoxemia
**Severe exacerbation of known CBD
*'''Discharge with close follow-up:'''
**Stable known CBD patient with mild symptoms at baseline
**Suspected CBD in a stable patient — arrange:
***Occupational medicine or pulmonology referral (ideally to a center with beryllium disease expertise) within 1–2 weeks
***BeLPT testing (requires specialized lab — coordinate with occupational medicine)
***HRCT if not performed
***PFTs with DLCO
**Minor skin exposure — irrigate thoroughly; refer to occupational medicine for BeLPT screening
*'''Discharge counseling:'''
**Return for worsening dyspnea, fever, or new respiratory symptoms
**'''Avoid further beryllium exposure''' — discuss with employer and occupational health
**If diagnosed with sarcoidosis previously and any beryllium exposure history exists, inform referring physician to order BeLPT
**Smoking cessation (beryllium is a lung carcinogen; smoking compounds risk)

==See Also==
*[[Sarcoidosis]]
*[[Pneumoconiosis]]
*[[Silicosis]]
*[[Asbestosis]]
*[[Toxic inhalation]]
*[[Hypersensitivity pneumonitis]]
*[[ARDS]]
*[[Heavy metal toxicity]]

==External Links==
*[https://www.ncbi.nlm.nih.gov/books/NBK470364/ Berylliosis — StatPearls]
*[https://www.atsjournals.org/doi/10.1164/rccm.201409-1722ST ATS Statement: Diagnosis and Management of Beryllium Sensitivity and CBD (2014)]
*[https://www.osha.gov/beryllium/health-effects Beryllium Health Effects — OSHA]
*[https://www.merckmanuals.com/professional/pulmonary-disorders/environmental-and-occupational-pulmonary-diseases/beryllium-disease Beryllium Disease — Merck Manual Professional]
*[https://rarediseases.org/rare-diseases/berylliosis/ Berylliosis — NORD]
*[https://www.atsdr.cdc.gov/toxprofiles/tp04.pdf Toxicological Profile for Beryllium — ATSDR]

==References==
<references/>

[[Category:Toxicology]]
[[Category:Pulmonary]]

Beryllium toxicity - Revision history

Danbot: Strip excess bold

Danbot: Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template